Trump Shatters Decades Ban – UNLEASHES Psychedelics

President Trump just unlocked psychedelic drugs like ibogaine for veterans’ PTSD, shattering decades of federal bans in a move that could save countless lives from suicide.

Story Snapshot

Trump signed executive order on April 18, 2026, expediting FDA review of three psychedelic compounds for mental illness.
Targets veterans with PTSD and treatment-resistant conditions; includes $50 million ARPA-H funding.
Joe Rogan and Marcus Luttrell attended Oval Office ceremony, signaling veteran and public support.
Combines FDA priority vouchers, Right to Try access, and DEA rescheduling pathways.
First federal action to fast-track psychedelics after clinical trial successes.

Executive Order Signing Ceremony

President Donald Trump signed the executive order on April 18, 2026, in the Oval Office. High-profile guests Joe Rogan and former Navy SEAL Marcus Luttrell stood by as Trump directed federal agencies to accelerate psychedelic access. FDA Commissioner Mary Makary announced immediate review of three compounds. Trump quipped during the event, “Can I have some, please? I’ll take some,” highlighting the urgency for mental health breakthroughs. This action prioritizes veterans facing PTSD and suicide crises.

Historical Shift from Schedule I Restrictions

Psychedelics like LSD, ibogaine, and ecstasy faced Schedule I classification since the 1960s, labeled with no medical use. Recent FDA Breakthrough Therapy designations changed that, based on clinical trials showing promise for treatment-resistant depression and PTSD. Veterans’ advocacy and state programs built momentum. Trump’s order marks the first major federal push, aligning innovation with common-sense support for proven therapies over endless bureaucracy.

Core Components of the Order

FDA issues National Priority Vouchers for 1-2 month reviews of qualifying psychedelics. Right to Try Act opens access for eligible patients to investigational drugs like ibogaine after basic safety checks. ARPA-H allocates $50 million to match state research investments. Agencies including DEA, HHS, and VA must boost clinical trials and data sharing. Attorney General initiates rescheduling post-Phase 3 success. Trump called it “historic reforms” for new treatments.

Commissioner Makary stressed science drives speed: applications arrive soon, with no corners cut on safety. This balances urgency with rigor, a conservative win for evidence-based policy over ideological bans.

Impacts on Veterans and Patients

Veterans lead as priority group, tackling elevated suicide rates where standard therapies fail. Short-term, three compounds enter fast-track review; patients access treatments via Right to Try. Long-term, successful trials could reschedule drugs, spawn therapy clinics, and set precedents for innovation. Biotech firms gain markets; states get federal matching funds. Broader effects legitimize psychedelics in healthcare, influencing global policy.

Trump Signs Psychedelics Order https://t.co/Iva6TdQYaN via @reason

— Boomertarian Norm (@BoomertarianN) April 21, 2026

Joe Rogan’s presence underscores mainstream backing; his ibogaine push via text to Trump spurred action. Luttrell represents SEALs endorsing real solutions for trauma. FDA’s prior approvals signal compounds’ advanced safety data, justifying acceleration without risking public health.